An experimental anticancer drug appears to have been cured in all patients in a clinical trial in the United States. Dostarlimab is a monoclonal antibody that has been shown to completely eliminate colorectal cancer in patients in this trial.
In a clinical trial, all patients were treated for non-metastatic breast cancer with du dostarlimab, an immunotherapy monoclonal antibody produced by rocket biotechnology by giant GSK, are in remission six to twenty-five months after treatment. With a better tolerance for standard treatment based on radiochemotherapy and surgery.
“Dr. Luis A. Diaz Jr., author of a paper published Sunday in the NEJM, which describes the results, said he was unaware of any other study in which a treatment would completely destroy a cancer in every patient: “I think this is the first time this is happening. it happened in the history of cancer. ” https://t.co/0ckpGY5tS0
– Heather Jameson (@hjamesdc) June 6, 2022
“I think this is the first time this has happened in the history of cancer.” Dr. Luis A. Diaz Jr. of the Memorial Sloan Kettering Cancer Center does not hide his enthusiasm for the results of this clinical trial.
With other physicians, an article is published in the New England Journal of Medicine in a clinical trial conducted on a dozen colorectal cancer patients in the United States.
Major cancer discovery: new antibody blocks tumor growth and metastasis, hopes for new treatment
These patients with rectal cancer had to deal with exhausting treatments – chemotherapy, radiation therapy, with the fear of surgery with serious consequences.
A great medical premiere that deals with the treatment of colorectal cancer
The results were amazing. The cancer went away in every patient.
The American study, presented Sunday, June 5 at the ASCO Cancer Congress (in Chicago, USA) and published at the same time in the New England Journal of Medicine, refers to a new, hope for many patients.
What is eleucerobin, that molecule that could become a cure for cancer?
The patients concerned were affected by particular tumors. If the results are confirmed, it will revolutionize the treatment of this subgroup of colorectal cancers. Especially since this tumor abnormality is more common in colorectal cancers, but it also exists in other cancers. Hence the hope that the treatment also serves to treat other types of cancers.